Arcutis Biotherapeutics, Inc.
ARQT· Nasdaq· Pharmaceutical Preparations
- Market cap
- –
- P/FCF
- –
- EV/Sales
- –
- FCF margin
- -1.7%
- ROIC, 5 yr avg
- –
- Revenue, 5 yr CAGR
- –
We record prices for the companies we cover; ARQT is not one of them yet.
Company statistics
Profile · FY2025
- Market cap
- –
- Enterprise value
- –
- Diluted shares
- 127.2M
- Revenue
- $376.1M
- Free cash flow
- -$6.3M
- Owner earnings
- -$46.7M
Valuation · FY2025
- P/E
- –
- P/FCF
- –
- P/Owner earnings
- –
- EV/Sales
- –
- EV/FCF
- –
- P/B
- –
Margins · FY2025
- Gross
- –
- Operating
- -3.3%
- Net
- -4.3%
- Free cash flow
- -1.7%
- Owner earnings
- -12.4%
- Stock pay
- 10.7%
Returns
- ROIC, FY2025
- –
- ROIC, 5 yr avg
- –
- ROE, FY2025
- -8.5%
- ROE, 5 yr avg
- -122.2%
Growth (CAGR)
- Revenue, 3 yr
- 367.3%
- Revenue, 5 yr
- –
- Revenue, 7 yr
- –
- Diluted EPS, 3 yr
- –
- Diluted EPS, 5 yr
- –
- Diluted EPS, 7 yr
- –
- Free cash flow, 3 yr
- –
- Free cash flow, 5 yr
- –
- Free cash flow, 7 yr
- –
Financial health · FY2025
- Cash and investments
- $221.0M
- Total debt
- $109.0M
- Net cash
- $112.0M
- Debt/Equity
- 0.6x
- Debt/FCF
- –
Shareholder returns · FY2025
- Dividend yield
- –
- Payout ratio
- –
- Buyback yield
- –
- Shareholder yield
- –
- Share count, 5 yr
- 29.0%
Financials: ten years from the 10-Ks
Revenue
$376.1M
FY2025
FY2018FY2025
Margins
Operating-3.3%Net-4.3%
FY2025
FY2018FY2025
Free cash flow and owner earnings
Free cash flow-$6.3MOwner earnings-$46.7M
FY2025
FY2018FY2025
Diluted shares
127.2M
+6802.8% over 7 years, net dilution
FY2018FY2025
Net cash
$112.0M
$112.0M more cash than debt
FY2018FY2025
Every figure, year by year
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| The business | ||||||||
| Revenue | – | – | $0 | $0 | $3.7M | $59.6M | $196.5M | $376.1M |
| Revenue growth | – | – | – | – | – | 1517.1% | 229.7% | 91.3% |
| Gross margin | – | – | – | – | – | – | – | – |
| Operating margin | – | – | – | – | -8183.0% | -404.5% | -65.3% | -3.3% |
| Net income | -$19.3M | -$42.0M | -$135.7M | -$206.4M | -$311.5M | -$262.1M | -$140.0M | -$16.1M |
| Net margin | – | – | – | – | -8449.8% | -439.8% | -71.3% | -4.3% |
| Diluted EPS | – | $-22.78 | $-3.80 | $-4.18 | $-5.66 | $-3.78 | $-1.16 | $-0.13 |
| Return on invested capital? | – | – | – | – | – | – | – | – |
| Cash | ||||||||
| Operating cash flow | -$14.1M | -$42.8M | -$113.0M | -$174.6M | -$257.7M | -$247.1M | -$112.2M | -$5.6M |
| Capital expenditure | $0 | $295.0K | $321.0K | $995.0K | $333.0K | $428.0K | $143.0K | $686.0K |
| Free cash flow | -$14.1M | -$43.1M | -$113.4M | -$175.6M | -$258.0M | -$247.5M | -$112.3M | -$6.3M |
| Stock-based compensation | $151.0K | $824.0K | $7.9M | $23.9M | $32.7M | $38.8M | $41.7M | $40.4M |
| Owner earnings? | -$14.2M | -$44.0M | -$121.3M | -$199.5M | -$290.7M | -$286.3M | -$154.0M | -$46.7M |
| Free cash flow per share | – | $-23.40 | $-3.18 | $-3.55 | $-4.69 | $-3.57 | $-0.93 | $-0.05 |
| Capital allocation | ||||||||
| Dividends paid | – | – | – | – | – | – | – | – |
| Share repurchases | – | – | – | – | – | – | – | – |
| Diluted shares | – | 1.8M | 35.7M | 49.4M | 55.0M | 69.3M | 121.0M | 127.2M |
| Share count change? | – | – | 1835.1% | 38.5% | 11.4% | 25.9% | 74.5% | 5.2% |
| Balance sheet | ||||||||
| Cash and equivalents | $39.4M | $63.3M | $65.1M | $96.4M | $53.6M | $88.4M | $71.3M | $42.9M |
| Short-term investments | – | $37.9M | $219.4M | $290.6M | $355.9M | $183.5M | $156.6M | $178.1M |
| Total debt | – | – | $0 | $72.3M | $197.8M | $201.8M | $107.2M | $109.0M |
| Net debt | – | – | -$284.4M | -$314.7M | -$211.8M | -$70.1M | -$120.8M | -$112.0M |
| Shareholders' equity | -$24.0M | -$65.0M | $270.6M | $297.7M | $209.6M | $88.7M | $157.5M | $189.5M |
Latest filings
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Earnings release |
| 2026-05-06 | 10-Q | Quarterly report |
| 2026-04-21 | DEF 14A | Proxy statement |
| 2026-02-25 | 10-K | Annual report |
| 2026-02-25 | 8-K | Earnings release |
| 2025-10-28 | 10-Q | Quarterly report |
| 2025-10-28 | 8-K | Earnings release |
| 2025-08-06 | 10-Q | Quarterly report |
| 2025-08-06 | 8-K | Earnings release |
More from our coverage
- MSFTPlatforms8.4MicrosoftThe most entrenched software franchise in the enterprise, now spending its cash flow on AI capacity; a great business we would own with a margin of safety, not at any price.Base value $410.29
- NVDAAI infrastructure8.4NVIDIAThe best business in technology at the top of its cycle: the moat is CUDA as much as silicon, but today's margins are a peak, not a floor.Base value $104.32
- AAPLHardware7.6AppleOne of the highest-quality businesses in the world growing in the low single digits; the price usually assumes more growth than the numbers show.Base value $134.27
- GOOGLPlatforms7.4AlphabetSearch pays for everything, and AI is both its biggest threat and its biggest opportunity; the price has to allow for search being worth less than it was.Base value $209.60
- NOWSoftware7.4ServiceNowA rare enterprise platform still growing above 20% with high retention; the free cash flow is real but stock pay takes a large share of it.Base value $189.13
- ADBESoftware7.4AdobeSuperb margins and a shrinking share count, priced for decline; the question is whether AI makes Adobe's tools more valuable or makes them unnecessary.Base value $449.35
